Several new variants of SARS-CoV-2 virus have emerged in recent months. The U.K. variant B.1.1.7, the Brazil variant P.1, the South Africa variant B.1.351, and the most recent Indian variant B.1.617 are particularly concerning because of their high prevalence. A subset of the mutations identified in the RBD domain of the spike protein occurs in more than one strain. These convergent mutations are highly interesting because they may be the cause of the increased transmissibility.
Sino Biological has launched RBD and Spike proteins of these variants.

The mutations in these strains also occur in the nucleocapsid protein, which is commonly used as the biomarker in rapid antigen tests. It’s critical to assess whether the current commercial antigen tests can detect the mutated N proteins with the same sensitivity and specificity as their WT counterpart.

Contact us for more information.